Drugs / VULINACIMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03494231 | Mar 2018 → May 2019 | cancer | Henlix, Inc | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VULINACIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594548 ↗ |
| Known as | HLX06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03494231 ↗ |
| Action | Inhibit | “HLX06 has shown growth inhibition of tumors in xenogeneic studies.” NCT03494231 ↗ |
| Modality | Monoclonal antibody | “recombinant fully human anti-VEGFR2 monoclonal antibody against cancers” NCT03494231 ↗ |
| Route | Intravenous | “Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week.” NCT03494231 ↗ |